Results 41 to 50 of about 3,401,781 (173)
<div>AbstractPurpose:<p>Target-dependent TCB activity can result in the strong and systemic release of cytokines that may develop into cytokine release syndrome (CRS), highlighting the need to understand and prevent this complex clinical syndrome.</p>Experimental Design:<p>We explored the cellular and molecular players involved ...
Marina Bacac +22 more
openaire +1 more source
Cytokine release syndrome (CRS) is a well-described immune-related adverse event following chimeric antigen receptor T-cell therapy, but has rarely been reported following anti-programmed death ligand-1 therapy.
Chul Kim, Paul Sackstein, Jacob Zaemes
doaj +1 more source
Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome
Background: Cytokine storm in COVID-19 is heterogenous. There are at least three subtypes: cytokine release syndrome (CRS), macrophage activation syndrome (MAS), and sepsis. Methods: A retrospective study comprising 276 patients with SARS-CoV-2 pneumonia.
Oleksandr Oliynyk +5 more
doaj +1 more source
IL1 Blockade May Ameliorate Cytokine Release Syndrome
Targeting IL1 attenuates cytokine release syndrome (CRS) without affecting CAR T-cell antitumor activity.
core +1 more source
Pathogenesis of IL-6 and potential therapeutic of IFN-γ in COVID-19
The elevated inflammatory cytokines suggest that a cytokine storm, also known as cytokine release syndrome (CRS), may play a major role in the pathology of pandemic Coronavirus Disease (COVID-19) leading to cause Acute respiratory distress syndrome (ARDS)
Ahmed Hasan Mohammed
doaj
Cytokine release syndrome (CRS) is a severe and life‐threatening toxicity typically reported in chimeric antigen receptor T cell therapy and is rarely reported in immune checkpoint inhibitor (ICI) therapy.
Toshiharu Tsutsui +5 more
doaj +1 more source
Apoptotic Cells for the Prevention of Cytokine Release Syndrome (CRS) in CAR T-Cell Therapy
Abstract Background: Chimeric antigen receptor (CAR)-modified T cells with specificity against CD19 have demonstrated dramatic promise against highly refractory hematologic malignancies. Clinical responses with complete remission rates as high as 90% have been reported in children and adults with relapsed/refractory acute lymphoblastic ...
Dror Mevorach +2 more
openaire +1 more source
Cytokine release syndrome (CRS) is an acute systemic inflammatory syndrome characterized by fever and organ dysfunction. CRS is increasingly recognized as an immune-related adverse event caused by the use of immune checkpoint inhibitors (ICIs) to treat ...
Takanori Ito +7 more
doaj +1 more source
Chimeric antigen receptor (CAR) T-cell therapy has yielded impressive outcomes and transformed treatment algorithms for hematological malignancies.
Xinyi Xiao +6 more
doaj +1 more source
The role of cytokines in cytokine release syndrome (CRS) after CAR T cell therapy
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment landscape for hematological malignancies. However, cytokine release syndrome (CRS) remains a common and potentially severe toxicity, significantly affecting patient safety and requiring intensive clinical management.
Gabriel, Kathrin +4 more
openaire +3 more sources

